3 results
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…
Primary objectives:The primary aims of this study are to explore the relation of the extent of VS dopamine release and amphetamine-induced behavioral responses and to characterize the PD effect of repeat-dose amphetamine in healthy subjects.…
To evaluate the efficacy of ACZ885 plus MTX by assessing the response to treatment (ACR50) as compared to MTX alone in early RA patients after 6, 14 and 26 weeks of treatment. The study aims to evaluate the clinical response in this RA subpopulation…